Columbia and NewYork-Presbyterian to participate in program led by the Foundation for the National Institutes of Health Biomarkers Consortium
The National Institutes of Health has awarded a three-year, $424,081 grant to Magda El-Shenawee, electrical engineering professor, for her work on an intraoperative and rapid method of detecting positive cancer margins during conservative breast cancer surgery, or lumpectomy.
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
In a research effort that merged genetics, physics and information theory, a team at the Schools of Medicine and Engineering at Johns Hopkins University has added significantly to evidence that large regions of the human genome have built-in variability in reversible epigenetic modifications made to their DNA
The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma. Dr. Paul Nghiem, a senior investigator on the clinical trial that led to yesterday’s fast-track FDA approval and an expert on MCC is available for interviews, as is a patient who participated in the clinical trial.
Researchers predict that 13,500 new cases of colon and rectal cancers will be diagnosed in Americans under age 50 this year; in all age groups, about 100,000 cases of colon cancer and nearly 40,000 cases of rectal cancer are expected.
Colorectal cancer is the second leading cause of cancer death for men and women in the United States according to the American Cancer Society (ACS). In fact, the ACS estimates that 134,490 people in the United States were diagnosed with colorectal cancer in 2016, including 70,820 men and 63,670 women. In addition, the ACS estimates that 49,190 people, 26,020 men and 23,170 women, died from colorectal cancer in 2016.
Applications by the IMP, the Research Institute of Molecular Pathology in Vienna, were 100% successful in the latest call of the European Research Council ERC. Over the coming five years, projects by Senior Scientists Meinrad Busslinger and Elly Tanaka will be funded with 4.8 million euros.
In a new study published today in JCI Insight, UC Davis researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first.
UVA researchers have again shown that a part of the body thought to be disconnected from the immune system actually interacts with it, and that discovery helps explain cases of male infertility, certain autoimmune diseases and even the failure of cancer vaccines.
Study results indicate importance of treatment based on genetic mutation rather than location of origin
AMP has published consensus recommendations that will help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CAR T-cell cancer immunotherapy pioneer, Dr. Carl H. June, M.D., will join its scientific advisory board to help guide applications of the company's technology in the treatment of cancer.
Building on their previous research focusing on vaccination within a tumor (intratumoral) for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early stage resected pancreatic cancer, intratumoral vaccination induces an anti-tumor response that results in a significant improvement in overall survival.
A new study led by University of Kentucky Markey Cancer researchers and published in the Journal of Cell Science establishes a novel link between cell polarity and cancer-associated inflammation.
Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid-derived suppressor cells (MDSCs).
Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models. Reporting results March 20 in Nature Medicine, researchers at Cincinnati Children’s Hospital Medical Center suggest that blocking the signaling proteins c-Fos and Dusp1 as part of combination therapy might cure several types of kinase-driven, treatment-resistant leukemia and solid tumor cancers.
Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.
After evaluating more than 900 differences in the shape and structure of cancer cells, UT Southwestern Medical Center researchers developed a computer model able to predict the most deadly lung cancers based on a fraction of those features.
The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought.
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors (ICPIs) to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.
A summary of a select abstracts by Dana-Farber researchers being presented at 2017 AACR Annual Meeting in April
Unlike its viral cousins hepatitis A and B, hepatitis C virus (HCV) has eluded the development of a vaccine and infected more than 170 million people worldwide. Now, researchers at Johns Hopkins Medicine report that a novel laboratory tool that lets them find virus mutations faster and more efficiently than ever before has identified a biological mechanism that appears to play a big role in helping HCV evade both the natural immune system and vaccines.
Queen’s University Belfast scientists have discovered that specific cells from the immune system are key players in brain repair – a fundamental breakthrough that could revolutionise the treatment of debilitating neurological disorders such as Multiple Sclerosis (MS).
One reason we survive into adulthood is that cell-killing T cells usually recognize and eliminate cancerous or pathogen-infected cells. But prolonged overactivity of immune cells summoned to a tumor or infection site can render them useless to dispatch invaders, a cellular state immunologists call "exhaustion." Fortunately, cancer researchers are devising effective immunotherapies to counter exhaustion and re-motivate immune cells to eradicate a patient's tumor
When an infection attacks the body for the first time, T cells of the immune system help fight off that specific pathogen. After the infection has cleared, some of the T cells that fought the microbe transition into “memory” cells that remember the pathogen and are ready to protect the body from future infections. Previous research has found that memory T cells are critical for long-term immunity, but the quantity and quality of the cells mysteriously declines with time, making some individuals more likely to be reinfected. Now, researchers from the University of Missouri School of Medicine have identified a molecular mechanism that operates in memory T cells that could be manipulated to produce and maintain more memory T cells in the body, a finding that could improve vaccinations and cancer immunotherapies.
In a study published in journal Nature Immunology, UNC Lineberger researchers describe how inflammation can go unchecked in the absence of a certain inflammation inhibitor called NLRP12. In a harmful feedback loop, this inflammation can upset the balance of bacteria living in the gut.
Although Zika and dengue are considered different virus “species,” they are so closely related that the immune system treats Zika just like another version of dengue, report researchers at La Jolla Institute for Allergy and Immunology. Their latest study, published in the March 13, 2017, advance online edition of Nature Microbiology, shows that pre-existing immunity to dengue virus modulates the magnitude and breadth of the immune system’s T cell response to Zika.
Depressed patients with chronic rhinosinusitis (CRS) are more likely to miss days of work or school than those without depression symptoms, according to the results of a new study led by the Sinus Center at Massachusetts Eye and Ear.
People with asthma are likely to have worse symptoms when they get the flu because they have weaker immune systems, new Southampton research has shown.
Cabozantinib, an FDA-approved drug for patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils – the first-responders of the immune system – to infiltrate the tumor. This novel approach, utilizing the innate immune system, produced near-complete clearance of invasive prostate cancers within 48 to 72 hours.
In a new study in the journal Nature, Dana-Farber Cancer Institute scientists report that a compound able to reverse the allegiance of innate immune system cells – turning them from tumor enablers into tumor opponents – caused breast tumors in mice to shrink and withdraw from distant metastases.
Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.
Research by Rutgers University investigators – including a number from Rutgers Cancer Institute of New Jersey – has resulted in the development of small molecule inhibitors that block a protein involved in the development of some cancers. At focus are TAM receptors, which when overexpressed can make too many proteins leading to cancer development, drug resistance and overall poor patient survival.
Study shows typically ‘mild’ respiratory virus can turn into deadly pneumonia in this vulnerable population, points to need for effective meds, better prevention
Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable. Now, discoveries made by two Cancer Research Institute scientists could help make these and other immunotherapies even more transformative for patients.
UCLA scientists pioneered an approach to observe in real time what excites T cells at the nanoscale, pinpointed the pathway that controls immune response and identified drugs that could equip scientists with the ability to manipulate the immune system and control disease.
University of California, Irvine researchers have identified a specific mutation that allows melanoma tumor cells to remain undetected by the immune system.
Computer model shows what happens at the molecular level during severe allergic reactions to abacavir, a common HIV drug
A new international study co-led by a Rush University Medical Center researcher suggests that a drug starting through the pipeline could ameliorate or even eliminate the symptoms in most sufferers.
The NCCN Oncology Research Program has awarded grants for its first-ever multi-industry collaborative project, soliciting investigator-initiated proposals to research the effectiveness of Boehringer Ingelheim’s afatinib in combination with other drugs to treat lung and head and neck cancers.
A chemical found in tumors may help stop tumor growth, according to a new study. Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune system’s T-cells and caused primary tumors and metastatic tumors in the liver to shrink.
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in Science Translational Medicine.
As we head into allergy season, you may feel less likely to grab a hanky and sneeze. That’s because new University of Florida research shows a probiotic combination might help reduce hay fever symptoms, if it’s taken during allergy season.
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells and the second most common type of leukemia in children and adults.
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
Hepatocellular carcinoma is the most common form of liver cancer, but treatment options are limited and many patients are diagnosed in late stages when the disease can’t be treated. Now, University of Missouri School of Medicine researchers have developed a new treatment that combines chemotherapy and immunotherapy to significantly slow tumor growth in mice. The researchers believe that with more research, the strategy could be translated to benefit patients with the disease.
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new regulator of the innate immune response—the immediate, natural immune response to foreign invaders. The study, published recently in Nature Microbiology, suggests that therapeutics that modulate the regulator—an immune checkpoint—may represent the next generation of antiviral drugs, vaccine adjuvants, cancer immunotherapies, and treatments for autoimmune disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right